However, it is unclear whether the beneficial effect
is largely due to early post-acute event combination therapy and
is smaller in the long term. Future studies will provide additional
data to assess whether specific subgroups (most notably patients
with coronary disease who have undergone percutaneous coronary
intervention) may benefit from long-term combined antiplatelet
therapy with clopidogrel and aspirin.